The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 9th 2024
Ipilimumab plus nivolumab increased response rates vs anti-PD1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.
Cemiplimab Nears EU Approval for CSCC
April 29th 2019The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.
Dr. Johnson on Promise of Combination Therapy in Melanoma
April 5th 2019Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.
SITC Guidelines Provide a Fresh Look at Evolving Strategies for Melanoma
New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer.
EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications
March 5th 2019The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.
New Targeted Therapy Duo Provides Advantages in BRAF-Mutant Melanoma
March 4th 2019Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.
Dr. Sullivan on Considerations for Treatment in Metastatic Melanoma
February 28th 2019Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses considerations for initial treatment of patients with metastatic melanoma.